Fcγ receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy.

Autor:	Stork AC; Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, The Netherlands., Notermans NC; Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, The Netherlands., van den Berg LH; Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, The Netherlands., Schellevis RD; Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, The Netherlands., Niermeijer JM; Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands., Nederend M; Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Leusen JH; Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., van der Pol WL; Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, The Netherlands.
Jazyk:	angličtina
Zdroj:	Journal of neurology, neurosurgery, and psychiatry [J Neurol Neurosurg Psychiatry] 2014 Aug; Vol. 85 (8), pp. 918-20. Date of Electronic Publication: 2014 Jan 31.
DOI:	10.1136/jnnp-2013-306958
Abstrakt:	Background: Treatment with anti-B cell antibody rituximab may ameliorate the disease course in a subgroup of patients with polyneuropathy associated with IgM monoclonal gammopathy. Polymorphisms of leukocyte IgG receptors (FcγR) that influence efficiency of antibody-dependent cell-mediated cytotoxicity determine rituximab efficacy in patients with lymphoma and autoimmune disease. Objective: To investigate the association of FcγRIIA and FcγRIIIA polymorphisms with the response to rituximab treatment in a cohort of patients with polyneuropathy associated with IgM monoclonal gammopathy (PNP-IgM) with and without antimyelin-associated glycoprotein antibodies. Methods: We determined FcγRIIA-R/H131 and FcγRIIIA-V/F158 genotypes in 27 patients with PNP-IgM using allele-specific PCR and Sanger sequencing. Results: The FcγRIIIA-V/V158 genotype was associated with functional improvement (p=0.02) after 1 year. Conclusions: FcγRIIIA polymorphisms are potential biomarkers for response to rituximab treatment in polyneuropathy associated with IgM monoclonal gammopathy. (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu